Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
The Journal Of Experimental Medicine
Tissino, Erika E; Benedetti, Dania D; Herman, Sarah E M SEM; Ten Hacken, Elisa E; Ahn, Inhye E IE; Chaffee, Kari G KG; Rossi, Francesca Maria FM; Dal Bo, Michele M; Bulian, Pietro P; Bomben, Riccardo R; Bayer, Elisabeth E; Härzschel, Andrea A; Gutjahr, Julia Christine JC; Postorino, Massimiliano M; Santinelli, Enrico E; Ayed, Ayed A; Zaja, Francesco F; Chiarenza, Annalisa A; Pozzato, Gabriele G; Chigaev, Alexandre A; Sklar, Larry A LA; Burger, Jan A JA; Ferrajoli, Alessandra A; Shanafelt, Tait D TD; Wiestner, Adrian A; Del Poeta, Giovanni G; Hartmann, Tanja Nicole TN; Gattei, Valter V; Zucchetto, Antonella A
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Jama Oncology
Maddocks, Kami J KJ; Ruppert, Amy S AS; Lozanski, Gerard G; Heerema, Nyla A NA; Zhao, Weiqiang W; Abruzzo, Lynne L; Lozanski, Arletta A; Davis, Melanie M; Gordon, Amber A; Smith, Lisa L LL; Mantel, Rose R; Jones, Jeffrey A JA; Flynn, Joseph M JM; Jaglowski, Samantha M SM; Andritsos, Leslie A LA; Awan, Farrukh F; Blum, Kristie A KA; Grever, Michael R MR; Johnson, Amy J AJ; Byrd, John C JC; Woyach, Jennifer A JA